401 related articles for article (PubMed ID: 18162241)
21. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Flaherty DK; Alkhateeb FM
Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
[TBL] [Abstract][Full Text] [Related]
23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
24. HPV vaccination - a paradigm shift in public health.
May J
Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
[TBL] [Abstract][Full Text] [Related]
25. Cervical cancer vaccination indications, efficacy, and side effects.
Bayas JM; Costas L; Muñoz A
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S11-4. PubMed ID: 18586311
[TBL] [Abstract][Full Text] [Related]
26. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
27. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
Hampl M
Minerva Med; 2007 Apr; 98(2):121-30. PubMed ID: 17519854
[TBL] [Abstract][Full Text] [Related]
28. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
[TBL] [Abstract][Full Text] [Related]
29. Assessing human papillomavirus vaccine efficacy and safety.
Hendrix SL
J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus vaccines.
Schmiedeskamp MR; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1344-52. PubMed ID: 16849621
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
32. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
34. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
35. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic HPV vaccines: new interventions for cancer control.
Barr E; Sings HL
Vaccine; 2008 Nov; 26(49):6244-57. PubMed ID: 18694795
[TBL] [Abstract][Full Text] [Related]
37. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E
Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950
[TBL] [Abstract][Full Text] [Related]
38. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
Pomfret TC; Gagnon JM; Gilchrist AT
J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccines and anal carcinoma.
Franceschi S; De Vuyst H
Curr Opin HIV AIDS; 2009 Jan; 4(1):57-63. PubMed ID: 19339940
[TBL] [Abstract][Full Text] [Related]
40. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
